Insider Transactions Reported | Ptc Therapeutics(PTCT)saw insider trading activity on 9/11/2025

Ptc Therapeutics(PTCT) saw insider trading activity on 9/11/2025, there were 2 insider trades during the day.

【History Insider Transaction】

Declare date	Position	Name	Buy/Sell	Quantity	Price per share/USD	Total Amount/USD
9/11/2025	--	SOUTHWELL DAVID P	Buy	12000	30.86	370.32k
9/11/2025	--	SOUTHWELL DAVID P	Sell	12000	58.34	700.08k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Sell	6017	56.91	342.43k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Buy	8528	18.01	153.59k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Sell	1238	56.85	70.38k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Buy	20411	30.86	629.88k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Buy	8423	11.23	94.59k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Buy	2488	11.32	28.16k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Sell	1250	56.86	71.08k
9/9/2025	CHIEF BUSINESS OFFICER	Pauwels Eric	Sell	14647	56.92	833.71k

[Company Profile]
Ptc Therapeutics, Inc. was incorporated as a Delaware corporation on March 31, 1998. PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. While the company's discovery programs are directed at targets in multiple therapeutic areas, the company is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. The company leads product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation.